Infliximab significantly improves joint and skin involvement in psoriatic, arthritis to a substantial extent and irrespective of baseline joint involvement or MTX use: Analysis of clinical response from the IMPACT2 trial

被引：0
|
作者：
Kavanauagh, A
Krueger, GG
De Vlam, K
Birbara, C
Beutler, A
Guzzo, C
Zhou, B
Dooley, L
Antoni, C
机构：
[1] UCSD, Div Rheumatol Allergy & Immunol, San Diego, CA USA
[2] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA
[3] Univ Hosp KU, Louvain, Belgium
[4] Univ Massachusetts, Sch Med, Worcester, MA USA
[5] Centocor Inc, Malvern, PA 19355 USA
[6] Univ Erlangen Nurnberg, Erlangen, Germany
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S617 / S617
页数：1
相关论文
共 10 条
  • [1] Infliximab improves skin involvement in psoriatic arthritis regardless of baseline psoriasis severity: Subanalysis of skin response from the IMPACT 2 trial
    Papp, K
    Joshi, S
    Guzzo, C
    Krueger, G
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P188 - P188
  • [2] Patterns of joint involvement and clinical response to MTX therapy in psoriatic arthritis.
    Citera, G
    Rosemffet, M
    Murgas, J
    Ortiz, Z
    Sosa, RF
    Scheines, E
    Cocco, JAM
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1366 - 1366
  • [3] CORRELATION BETWEEN SKIN INVOLVEMENT, JOINT INVOLVEMENT AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POST-HOC ANALYSIS OF EQUATOR/EQUATOR2
    Mease, P. J.
    Coates, L. C.
    Van den Bosch, F.
    Gladman, D. D.
    Gheyle, L.
    Trivedi, M.
    Alani, M.
    Vetters, E.
    Le Brun, F. O.
    Besuyen, R.
    Helliwell, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 792 - 792
  • [4] Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: Results from the IMPACT 2 trial.
    Mease, P
    Kavanaugh, A
    Krueger, GG
    Shergy, W
    Halter, D
    De Vlam, K
    Kirkham, B
    Bala, M
    Beutlers, A
    Guzzo, C
    Zhou, B
    Dooley, L
    Antoni, C
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S616 - S616
  • [5] Two-year data: Infliximab maintains clinical response in psoriatic arthritis patients - An analysis of the year 2 data from the infliximab multinational psoriatic arthritis controlled trial (impact)
    Antoni, CE
    Kavanaugh, A
    Kirkham, B
    Tutuncu, Z
    Burmester, GR
    Schneider, U
    Furst, DE
    Molitor, J
    Keystone, E
    Gladman, D
    Manger, B
    Wassenberg, S
    Weier, R
    Wallace, D
    Weisman, MH
    Kalden, JR
    Smolen, J
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 82 - 82
  • [6] 2-year data: Infliximab maintains clinical response in psoriatic arthritis patients-data from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni, CE
    Kavanaugh, A
    Kirkham, B
    Tutuncu, ZN
    Burmester, G
    Schneider, U
    Furst, DE
    Moliter, J
    Keystone, EC
    Gladman, D
    Manger, B
    Wassenberg, S
    Weier, R
    Wallace, D
    Weisman, M
    Kalden, JR
    Smolen, JS
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S209 - S209
  • [7] Ixekizumab significantly improved quality of life and joint pain in patients with psoriatic arthritis, nail disease and distal interphalangeal joint involvement from SPIRIT-H2H
    Ritchlin, Christopher
    Kavanaugh, Arthur
    Kristensen, Lars Erik
    Merola, Joseph
    Strober, Bruce
    Lisse, Jeffrey
    Bolce, Rebecca
    Sapin, Christophe
    Pustizzi, Jennifer
    McGonagle, Dennis
    [J]. RHEUMATOLOGY, 2024, 63
  • [8] Association between Skin and Joint Involvement in Patients with Psoriatic Arthritis Treated with Adalimumab: Analysis of Data from a German Non-Interventional Study
    Thaci, Diamant
    Behrens, Frank
    Greger, Gerd
    Burkhardt, Harald
    Gnann, Holger
    Schopf, Rudolf
    Wittig, Bianca Maria
    [J]. DERMATOLOGY, 2015, 230 (03) : 213 - 221
  • [9] IS THERE AN ASSOCIATION BETWEEN SKIN AND JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH ADALIMUMAB? - DATA-ANALYSIS FROM A LARGE GERMAN NON-INTERVENTIONAL STUDY
    Behrens, F.
    Koehm, M.
    Thaci, D.
    Krummel-Lorenz, B.
    Greger, G.
    Wittig, B.
    Burkhardt, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 285 - 285
  • [10] Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
    Kavanaugh, A.
    Krueger, G. G.
    Beutler, A.
    Guzzo, C.
    Zhou, B.
    Dooley, L. T.
    Mease, P. J.
    Gladman, D. D.
    de Vlam, K.
    Geusens, P. P.
    Birbara, C.
    Halter, D. G.
    Antoni, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (04) : 498 - 505
1